Fireside Chat, Conference Presentation, Interview
The pace of innovation in biotech: Mirador’s Mark McKenna
- The company intends to assume risks that traditional big pharma avoids, leveraging AI, machine learning, and deep learning to potentially reshape healthcare more significantly than in the last century.
- Strategic plans include running experiments in parallel to accelerate decision-making, with a goal of extending longevity through data stratification over the next 20 years.
- Commercialization efforts focus on personalized medicine, targeting an increase in remission rates for inflammatory bowel disease from 10% to 25%.
- The organization anticipates that disclosing specific targets could lead to 10 companies in China mimicking their work due to the simplicity of modifying antibody sequences.
- Manufacturing capabilities are viewed as critical for species survival during pandemics, creating a risk that reliance on a single country, such as China for drug substances, is untenable.
- Market expectations indicate that about 75% of current drugs originated outside big pharma, though selling the company would likely result in the acquirer doubling patient size and extending the timeline by an additional four years.
- The standard drug development timeline remains approximately ten years, with the company believing it can operate faster than current industry standards.
- Economic observations note that roughly 50% of a $50,000 drug charge returns to insurance companies due to PBM, health plan, and pharmacy vertical integration.
- Systemic risks include a lack of willingness in big pharma to take necessary risks and a market structure where 86% of deals involve a single buyer.
- Strategic partnerships are limited to one buyer per deal, and the ecosystem is considered ready to support ambitious goals like a cancer moonshot.
- Policy expectations suggest a need to shift from high deductible plans to first-dollar coverage to prevent financial burdens on employees.
- Long-term optimism exists for improving human health by challenging global competitors, though the current start-to-finish process for most drugs remains lengthy.